Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Tredaptive (nicotinic acid/laropiprant) - Important Safety Information from Merck Sharp & Dohme as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
24/01/2013
Problem Or Issue:
Important Safety Information communication from Merck Sharp & Dohme on suspension and recommendation to discontinue treatment with Tredaptive (nicotinic acid/laropiprant).
Important Safety Information - Tredaptive (nicotinic acid/laropiprant)
« Back
Date Printed: 13/05/2024